Clinical Trial Search

Primary: Area Under the Plasma Drug Concentration-time Curve From 0 to 24 Hours Post-dose (AUC0-24) of Islatravir (ISL) — 0.114 hr*µmol/L

Primary: Phase 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 4; 3; 12; 22 Participants

Primary: Changes in Serum K+ Levels From Baseline — 0.029; 0.127 Milliequivalents Per Liter (mEq/l) — p=< 0.001

Primary: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events (AEs) — 2.4 percentage of participants

Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants

Primary: Healthcare Utilization Costs — 2920.30; 7512.30 US Dollars — p=<0.0001

Primary: Number of Participants Practicing Safe Lead Exposure Prevention Behaviors (Pre Test) — 1; 2; 5 Participants

Primary: Number of Patients With Pathologic Complete Response — 0; 2 Participants

Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L

Primary: Change in Clinically Significant Depressive Symptoms, as Measured by the Montgomery Asberg Depression Rating Scale (MADRS) — 19.37; 20.87; 14.88; 18.67 score on a scale…

Primary: Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With…

Primary: Visual Analog Scale (VAS) — -3.9 Centimeter

Primary: To Determine the Safety and Evaluate Toxicity of Fixed Doses for Phase I Patients — 1 Participants

Primary: OS From Date of Randomization Until Death From Any Cause - Number of Events — 229; 304; 422; 350 Participants — p=<0.0001

Primary: Number of Condomless Anal Sex Acts — 1.53; 1.45; 1.04; 1.63 condomless anal sex acts